Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Trial shows CAR T-cell therapy prolongs remission in paediatric relapsed or refractory ALL

Stephan Grupp • 5 Dec 2014
ASH 2014
Acute Lymphoblastic Leukemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Stephan Grupp (Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA) presents the results of a study that suggests chimeric antigen receptor (CAR) T cells targeting CD19 (CTL019) can elicit durable remissions in paediatric relapsed or refractory acute lymphocytic leukaemia (ALL).

More from Stephan Grupp

Patient selection for CAR-T in ALL
1:33
Patient selection for CAR-T in ALL
Stephan Grupp • 2 Sep 2021
The latest research in ALL cellular therapy
2:16
The latest research in ALL cellular therapy
Stephan Grupp • 2 Sep 2021
The future of treating pediatric ALL with CAR-T
1:21
The future of treating pediatric ALL with CAR-T
Stephan Grupp • 2 Sep 2021
The importance of common language for CAR-T
0:57
The importance of common language for CAR-T
Stephan Grupp • 18 Mar 2021

Related Videos

Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
10:54
Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
Samer Srour • 19 Sep 2026
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
NGS-MRD assessment and targeted treatment selection in ALL
1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
3:52
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
Bijal Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals